NLS PHARMACEUTICS LTD
*W EXP 02/02/202 · CUSIP H57830111
6
institutional holders
+0 vs Q2 2023
1.1m
shares reported held*
$113.5kreported value*
0 new
1 added
0 reduced
0 sold out
net bought ≈ $10.5k (+100.0k shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $0.11.
Trends to Q3 2023
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 9 |
| Q4 2022 | 6 |
| Q1 2023 | 6 |
| Q2 2023 | 6 |
| Q3 2023 | 6 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Bought or addedCut or sold out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q4 2022 | 0 | 3 |
| Q1 2023 | 3 | 1 |
| Q2 2023 | 0 | 2 |
| Q3 2023 | 1 | 0 |
Calls vs puts
Options held, notional value, last 4 quarters. P/C = puts ÷ calls
CallsPuts
Numbers
| Quarter | Calls | Puts | P/C |
|---|---|---|---|
| Q4 2022 | $239.8k | $0 | 0.00 |
| Q1 2023 | $0 | $0 | — |
| Q2 2023 | $0 | $0 | — |
| Q3 2023 | $0 | $0 | — |
Biggest buyers
| Hudson Bay Capital Management LP | Added | +100.0k |
Biggest sellers
| None |
Holders, Q3 2023
| Manager | Shares | Change |
|---|---|---|
| ARMISTICE CAPITAL, LLC 0.00% of their portfolio | 500.0k $52.6k | Unchanged |
| Hudson Bay Capital Management LP 0.00% of their portfolio | 200.0k $21.0k | Added +100.0k |
| Altium Capital Management LLC 0.01% of their portfolio | 200.0k $21.0k | Unchanged |
| Ayrton Capital LLC 0.12% of their portfolio | 170.1k $17.9k | Unchanged |
| CLEAR STREET LLC 0.00% of their portfolio | 8.6k $905 | Unchanged |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0.00% of their portfolio | 0 $0 | Unchanged |